UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 116

Sortiert nach

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Future oncology (London, England), 2018-01, Vol.14 (2), p.123-136

2018

Volltextzugriff (PDF)

Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder

Human molecular genetics, 2006-11, Vol.15 (21), p.3132-3145

2006

Volltextzugriff (PDF)

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

Annals of the New York Academy of Sciences, 2003-03, Vol.983 (1), p.84-100

2003

Volltextzugriff (PDF)

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models

Neoplasia (New York, N.Y.), 2017-09, Vol.19 (9), p.661-671

2017

Volltextzugriff (PDF)

In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Molecular cancer therapeutics, 2018-05, Vol.17 (5), p.1003-1011

2018

Volltextzugriff (PDF)

Differential DNA Hypermethylation of Critical Genes Mediates the Stage-Specific Tobacco Smoke-Induced Neoplastic Progression of Lung Cancer

Clinical cancer research, 2005-04, Vol.11 (7), p.2466-2470

2005

Volltextzugriff (PDF)

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Bioconjugate chemistry, 2017-05, Vol.28 (5), p.1371-1381

2017

Volltextzugriff (PDF)

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

EJNMMI research, 2018-08, Vol.8 (1), p.87-10, Article 87

2018

Volltextzugriff (PDF)

Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

Cancer, 2017-08, Vol.123 (16), p.3080-3087

2017

Volltextzugriff (PDF)

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy

Molecular cancer therapeutics, 2021-01, Vol.20 (1), p.203-212

2021

Volltextzugriff (PDF)

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Neoplasia (New York, N.Y.), 2016-12, Vol.18 (12), p.775-784

2016

Volltextzugriff (PDF)

Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody–Maytansinoid Conjugates

Bioconjugate chemistry, 2016-07, Vol.27 (7), p.1588-1598

2016

Volltextzugriff (PDF)

Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer

Cancer research (Chicago, Ill.), 2005-03, Vol.65 (5), p.1664-1669

2005

Volltextzugriff (PDF)

Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display

Cancer research (Chicago, Ill.), 2004-03, Vol.64 (5), p.1639-1646

2004

Volltextzugriff (PDF)

A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)

Molecular cancer therapeutics, 2018-03, Vol.17 (3), p.650-660

2018

Volltextzugriff (PDF)

Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs)

Bioorganic & medicinal chemistry letters, 2019-09, Vol.29 (17), p.2455-2458

2019

Volltextzugriff (PDF)

Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing

Bioconjugate chemistry, 2015-11, Vol.26 (11), p.2261-2278

2015

Volltextzugriff (PDF)

hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation

Cancer biology & therapy, 2009-04, Vol.8 (7), p.636-644

2009

Volltextzugriff (PDF)

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

ACS medicinal chemistry letters, 2019-10, Vol.10 (10), p.1393-1399

2019

Volltextzugriff (PDF)

hBub1 deficiency triggers a novel p53 mediated early apoptotic checkpoint pathway in mitotic spindle damaged cells

Cancer biology & therapy, 2009-04, Vol.8 (7), p.627-635

2009

Volltextzugriff (PDF)

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

ACS medicinal chemistry letters, 2019-10, Vol.10 (10), p.1393-1399

2019

Volltextzugriff (PDF)

Synthesis of Highly Potent N‑10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs)

ACS medicinal chemistry letters, 2019-08, Vol.10 (8), p.1211-1215

2019

Volltextzugriff (PDF)

Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody

Immunology, 2010-06, Vol.130 (2), p.231-242

2010

Volltextzugriff (PDF)

Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence

Current opinion in oncology, 2002-01, Vol.14 (1), p.65-72

2002

Volltextzugriff (PDF)

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1

Neoplasia (New York, N.Y.), 2016-12, Vol.18 (12), p.775-784

2016

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(111)
Buchkapitel
(5)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(79)
Life Sciences & Biomedicine
(73)
Humans
(48)
Female
(28)
Animals
(19)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Oncology
(18)
Male
(17)
Pharmacology & Pharmacy
(14)
Microbiology
(13)
Middle Aged
(12)
Pharmacology. Drug Treatments
(12)
Adult
(11)
Mice
(10)
Aged
(9)
Disease Models, Animal
(9)
Physical Sciences
(9)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(8)
Cell Line, Tumor
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models

In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Differential DNA Hypermethylation of Critical Genes Mediates the Stage-Specific Tobacco Smoke-Induced Neoplastic Progression of Lung Cancer

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody–Maytansinoid Conjugates

Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer

Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display

A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)

Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs)

Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing

hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

hBub1 deficiency triggers a novel p53 mediated early apoptotic checkpoint pathway in mitotic spindle damaged cells

Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing

Synthesis of Highly Potent N‑10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs)

Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody

Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1

Suchergebnisse filtern